Myriad Finishes Big Year With NICE Endorsement Of EndoPredict Breast Cancer Diagnostic
The UK's National Institute for Health and Care Excellence (NICE) has included Myriad Genetics' EndoPredict in its recommendations for guiding adjuvant chemotherapy decisions for certain early breast cancer patients. The recommendation comes just a few weeks after new data showing the long-term prognostic value of the EndoPredict test was presented at the San Antonio Breast Cancer Symposium. The company is also making progress on its Vectra rheumatoid arthritis prognostic system with the publication of a large commercial cohort and several clinical studies on development of the adjusted Vectra score.
You may also be interested in...
Myriad Genetics, Lumicell, and Agendia were among the companies with diagnostic technologies featured in the scientific presentations at the recent San Antonio Breast Cancer Symposium. New trials show that Myriad's EndoPredict can help identify patients who should not have preoperative chemotherapy. New Phase II data support Lumicell's LUM system for guiding excision of residual tumor and preventing cancer recurrence. Agendia's MammaPrint test proved cost-effective in the MINDACT trial.
A new report from the National Academies of Sciences, Engineering, and Medicine issued a new report on the urgent need for better representation of underrepresented populations in clinical trials and research.
Nicholas co-founded Boston Scientific in 1979 with John Abele. He served as the company’s CEO from 1979 until 1999 and as chairman until 2016.